Cyclopharm Director Increases Stake via Share Purchase Plan

The latest update is out from Cyclopharm Limited ( (AU:CYC) ).

Cyclopharm director Dianne Margaret Angus has increased her direct holding in the company through participation in a share purchase plan. She acquired 21,052 ordinary shares for a total consideration of $19,999.40 on 12 March 2026, lifting her stake from 22,323 to 43,375 shares.

The transaction was conducted as part of the company’s share purchase plan, rather than through on-market trading, and did not involve any disposal of existing shares or changes to interests in contracts. The move signals a higher personal financial commitment by the director, which may be interpreted by investors as a sign of confidence in Cyclopharm’s prospects and capital initiatives.

The most recent analyst rating on (AU:CYC) stock is a Hold with a A$0.69 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

More about Cyclopharm Limited

Cyclopharm Limited is an Australian-listed company operating in the medical sector, with its ordinary shares traded on the ASX. The company’s securities are held by directors and investors under standard market mechanisms, including participation in share purchase plans, reflecting ongoing capital management and alignment of director and shareholder interests.

Average Trading Volume: 89,869

Technical Sentiment Signal: Sell

Current Market Cap: A$88.05M

See more insights into CYC stock on TipRanks’ Stock Analysis page.